Wegovy^®

Name: Wegovy®
Brand: Mobile IV Medics
Price: 1799 USD
Availability: OutOfStock

Limited Supply

Brand name Semaglutide

Wegovy^® is clinically proven to help you lose weight. Mobile IV Medics pairs the power of your weight loss treatment with receiving dedicated 24/7 support and not having to wait at a doctors offices or pharmacies.

Your program summary

Telehealth Visits Treatment + Supplies 24/7 medical support Monthly check-ins

Monthly plan

$1,799/month

Billed & shipped every month

Get started

Cancel any time

How does this program work?

What is included in this program?

*Eligibility for treatment and program is determined by a licensed healthcare provider via telehealth consultation. Some may not be eligible for treatment. Referenced program outcomes are based on high quality clinical literature but results may vary. Packaging may be different than what is shown.

Important safety information

Wegovy^® safety information

Important Safety Information WEGOVY^® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity:

To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight.
To reduce excess body weight and maintain weight reduction long term in:
- Adults and pediatric patients aged 12 years and older with obesity
- Adults with overweight in the presence of at least one weight-related comorbid condition.

Limitations of Use:

Co-administration with other semaglutide-containing products or any GLP-1 receptor agonist is not recommended.
The safety and efficacy of coadministration with other products for weight management have not been established.
There is limited experience from clinical trials with WEGOVY^® in patients with a history of pancreatitis. It is unknown if patients with a history of pancreatitis are at a higher risk for development of pancreatitis on WEGOVY^®.

IMPORTANT SAFETY INFORMATION WARNING: RISK OF THYROID C-CELL TUMORS

See full prescribing information for complete boxed warning.

In rodents, semaglutide causes thyroid C-cell tumors in clinically relevant exposures. It is unknown whether WEGOVY^® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
WEGOVY^® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.

Do not take WEGOVY^® if you:

Have a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Have been diagnosed with Diabetes (Type 1)
Have been diagnosed with pancreatitis or history of pancreatitis
Have severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems with digesting food
Have a known allergy to semaglutide/any other GLP-1 drug or any of the inactive ingredients in WEGOVY^®. Inactive ingredients include: di-sodium phosphate dihydrate, sodium chloride, water for injection, and hydrochloric acid or sodium hydroxide may be added to adjust pH.
Have a history of suicidal attempts or active suicidal ideation

WARNINGS AND PRECAUTIONS

Acute Pancreatitis: Has occurred in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.
Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or insulin may be necessary. Inform all patients of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
Acute Kidney Injury: Has occurred. Monitor renal function when initiating or escalating doses of WEGOVY^® in patients reporting severe adverse gastrointestinal reactions or in those with renal impairment reporting severe adverse gastrointestinal reactions.
Hypersensitivity Reactions: Anaphylactic reactions and angioedema have been reported postmarketing. Discontinue WEGOVY® if suspected and promptly seek medical advice.
Females and males of reproductive potential: Discontinue WEGOVY^® at least 2 months before a planned pregnancy because of the long half-life of semaglutide.
Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue WEGOVY^® immediately.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: Has been reported in trials with WEGOVY^®. Patients with a history of diabetic retinopathy should be monitored.
Heart Rate Increase: Monitor heart rate at regular intervals.
Suicidal Behavior and Ideation: Monitor for depression or suicidal thoughts. Discontinue WEGOVY^® if symptoms develop.

Side Effects

Most common side effects (incidence ≥ 5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS

WEGOVY^® delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution.

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue WEGOVY^®.
Females and Males of Reproductive Potential: Discontinue WEGOVY^® at least 2 months before a planned pregnancy because of the long half-life of semaglutide.

GETTING STARTED

Weight Loss is as Easy as 1-2-3

Complete a secure questionnaire within 3 minutes.

Begin with a free 3-minute questionnaire

Complete a secure questionnaire to help the medical team personalize your treatment.

Fast and easy consultation with a licensed medical provider.

Fast and Easy Doctor Consultation

A licensed medical provider will review your questionnaire, discuss your goals, and guide your treatment plan from home.

Treatment delivered right to your doorstep

Get your prescription and supplies delivered to your door with careful handling to ensure quality.

What is included?

Physician consultation for personalized treatment program

Treatment medication and supplies delivered to you

Ongoing physician monitoring and check-ins

Treatment dose titration to meet weight loss goals (all doses same price)

24/7 personalized support

Best physician consultation for your well-being.

TESTIMONIALS

In Their Own Words: Real Results
from Real Patients

I started Semaglutide 3 months ago and have already seen a big difference in my weight loss goals!

Stephanie 34 years old

My Tirzepatide weight loss journey with Mobile IV Medics has been able to curb my appetite and I can proudly say I’m down 19lbs right now. The doctors are amazing and I have no doubt that I will hit my goals!

Lynne 41 years old

I’m down 14lbs using Mobile IV Medics’ weight loss program. I feel healthier and confident in myself!

Anna 52 years old

Knowing that Mobile IV Medics is physician owned and operated has given me the peace of mind on a brand that I can trust with my weight loss goals.

Margaret 46 years old

Signing up was so easy! Once I filled out my medical survey my doctor contacted me almost immediately and I was approved after the screening. My prescription even shipped the next day!

Timothy 49 years old

Ready to begin your weight
loss journey?

Get started today

WEIGHT MANAGEMENT SOLUTION

Other weight loss treatments

Semaglutide

Starting at less than $45/week

In stock

Compounded active ingredient in Wegovy^® and Ozempic^®

Get started Learn more

Tirzepatide

Starting at less than $70/week

In stock

Compounded active ingredient in Zepbound^® and Mounjaro^®

Get started Learn more

Ozempic^®

$1,499/month

Limited Supply

Brand name semaglutide, a GLP-1 with FDA-approval for improved glycemic control

Get started Learn more

Mounjaro^®

$1,399/month

Limited Supply

Brand name tirzepatide, a dual action GLP-1 & GIP with FDA-approval for glycemic control

Get started Learn more

Zepbound^®

$1,699/month

Limited Supply

Brand name tirzepatide, a dual action GLP-1 & GIP with FDA-approval for weight loss

Get started Learn more

Saxenda^®

$1,799/month

Limited Supply

Brand name liraglutide, a GLP-1 with FDA approval for weight loss

Get started Learn more

Unsure about the right treatment?

Our team can help. Answer a few quick questions about yourself, and we’ll guide you to the most suitable treatment option.

Discover your best treatment

GET IN TOUCH

833-483-7447 (Text Message) [email protected]

Quick Links

WE ACCEPT:

The services provided have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. The material on this website is provided for informational purposes only and is not medical advice. Always consult your physician before beginning any treatment or therapy program. Any designations or references to therapies are for marketing purposes only and do not represent actual products.

Terms & Conditions Cancellation Policy Sitemap Privacy Policy Cookie Policy (US) Find Us on the Web Back to Top

Wegovy®

Wegovy® safety information

Weight Loss is as Easy as 1-2-3

What is included?

In Their Own Words: Real Results from Real Patients

Other weight loss treatments

GET IN TOUCH

Quick Links

WE ACCEPT:

Wegovy^®

Wegovy^® safety information

In Their Own Words: Real Results
from Real Patients